WO1998050383A8 - Derives de 5-phenyl-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4 - Google Patents

Derives de 5-phenyl-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4

Info

Publication number
WO1998050383A8
WO1998050383A8 PCT/FR1998/000886 FR9800886W WO9850383A8 WO 1998050383 A8 WO1998050383 A8 WO 1998050383A8 FR 9800886 W FR9800886 W FR 9800886W WO 9850383 A8 WO9850383 A8 WO 9850383A8
Authority
WO
WIPO (PCT)
Prior art keywords
group
azabicyclo
oct
alkyl
oxadiazol
Prior art date
Application number
PCT/FR1998/000886
Other languages
English (en)
Other versions
WO1998050383A1 (fr
Inventor
Samir Jegham
Alistair Lochead
Alain Nedelec
Frederic Galli
Thierry Gallet
Original Assignee
Synthelabo
Samir Jegham
Alistair Lochead
Alain Nedelec
Frederic Galli
Thierry Gallet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9705537A external-priority patent/FR2763067B1/fr
Priority claimed from FR9705538A external-priority patent/FR2763069B1/fr
Application filed by Synthelabo, Samir Jegham, Alistair Lochead, Alain Nedelec, Frederic Galli, Thierry Gallet filed Critical Synthelabo
Priority to EP98924364A priority Critical patent/EP0980370A1/fr
Priority to AU76587/98A priority patent/AU7658798A/en
Priority to JP54777898A priority patent/JP2002504896A/ja
Publication of WO1998050383A1 publication Critical patent/WO1998050383A1/fr
Publication of WO1998050383A8 publication Critical patent/WO1998050383A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Composés répondant à la formule générale (I) dans laquelle R1 représente H, un alkyle ou un cycloalkylméthyle, X1 représente H ou un alcoxy, ou bien OR1 et X1 représentent ensemble un groupe -OCH2O-, -O(CH2)2-, -O(CH2)3-, -O(CH2)2O- ou -O(CH2)3O-, X2 représente H, un groupe amino ou un groupe -NHCO2R dans laquelle R représente un alkyle ou un phénylalkyle, X3 représente H ou un halogène, n représente le nombre 0, 1, 2 ou 3, et Het représente soit un groupe pyrrolidin-1-yle, soit un groupe pipéridin-1-yle éventuellement substitué, soit un groupe 1H-hexahydroazépin-1-yle, soit un groupe 8-azabicyclo[3.2.1]oct-8-yle, soit un groupe 4-(phénylméthyl)pipérazin-1-yle, soit un groupe 4-méthyl-hexahydro-1,4-diazépin-1-yle, soit un groupe 1,2,3,4-tétrahydroisoquinoléin-2-yle, soit un groupe 1-azabicyclo[2.2.2]-oct-3-yle. Application en thérapeutique. Ces composés sont utiles dans la prévention des désordres dans lesquels les récepteurs 5-HT4 sont impliqués, que ce soit au niveau du système nerveux central, du système gastro-intestinal, du système cardio-vasculaire ou du système urinaire.
PCT/FR1998/000886 1997-05-06 1998-05-04 Derives de 5-phenyl-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4 WO1998050383A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP98924364A EP0980370A1 (fr) 1997-05-06 1998-05-04 Derives de 5-phenyl-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4
AU76587/98A AU7658798A (en) 1997-05-06 1998-05-04 5-phenyl-1,3,4-oxadiazol-2(3h)-one derivatives and their use as 5-ht4 ligands
JP54777898A JP2002504896A (ja) 1997-05-06 1998-05-04 ５−フェニル−１，３，４−オキサジアゾール−２（３ｈ）−オン誘導体およびそれらの５−ｈｔ４リガンドとしての使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9705537A FR2763067B1 (fr) 1997-05-06 1997-05-06 Derives de 3-(1-azabicyclo[2.2.2] oct-3-ylalkyl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
FR9705538A FR2763069B1 (fr) 1997-05-06 1997-05-06 Derives de 1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
FR97/05537 1997-05-06
FR97/05538 1997-05-06

Publications (2)

Publication Number Publication Date
WO1998050383A1 WO1998050383A1 (fr) 1998-11-12
WO1998050383A8 true WO1998050383A8 (fr) 1999-04-22

Family

ID=26233510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1998/000886 WO1998050383A1 (fr) 1997-05-06 1998-05-04 Derives de 5-phenyl-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4

Country Status (4)

Country Link
EP (1) EP0980370A1 (fr)
JP (1) JP2002504896A (fr)
AU (1) AU7658798A (fr)
WO (1) WO1998050383A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015021559A8 (pt) 2013-03-15 2019-11-12 Monsanto Technology Llc compostos de azóis n-,c-dissubstituídos, composição nematicida aquosa, sementes e métodos para controlar nematódeos indesejados e para controlar ou prevenir uma infestação de nematódeos em um animal".

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8525844D0 (en) * 1985-10-19 1985-11-20 Beecham Group Plc Compounds
FR2719842B1 (fr) * 1994-05-10 1996-06-07 Synthelabo Sels quaternaires de dérivés de 1-azabicyclo [2.2.2] octane, leur préparation et leur application en thérapeutique.
WO1995032965A1 (fr) * 1994-06-01 1995-12-07 Yamanouchi Pharmaceutical Co. Ltd. Derive de l'oxadiazole et composition medicinale a base de ce dernier
DE69602970T2 (de) * 1995-11-09 2000-01-20 Sanofi-Synthelabo, Paris 5-(phenyl)-3-(4-piperidinyl)-1,3,4-oxadiazol-2(3h)-on-derivate verwendbar als 5-ht4- oder h3-rezeptorliganden

Also Published As

Publication number Publication date
AU7658798A (en) 1998-11-27
WO1998050383A1 (fr) 1998-11-12
JP2002504896A (ja) 2002-02-12
EP0980370A1 (fr) 2000-02-23

Similar Documents

Publication Publication Date Title
WO1994011502A3 (fr) Kinases du type recepteurs activine, proteines possedant des domaines de kinase de serine/threonine et leur utilisation
PH25289A (en) 3-substituted and optionally 1-substituted azacyclic and azabicyclic compounds, pharmaceutical composition thereof and their use as stimulants of cognitive functions
ZA94711B (en) Heterocyclic compounds and their preparation and use
WO2001023387A3 (fr) PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES A SUBSTITUTION ALKYLENE-DIAMINE ET PYRAZOLO[1,5-a]-1,3,5-TRIAZINES
WO2001023388A3 (fr) Pyrazolo[1,5,-a]-1,5-pyrimidines et pyrazolo[1,5-a]-1,3,5-triazines amino substituees
WO2001066543A3 (fr) Derives de 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane
ATE207897T1 (de) Piperidinderivate als neurokininantagonisten
AU7406596A (en) Heterocyclic compounds having tachykinin receptor antagonist activity, their preparation and their use
CA2168432A1 (fr) Composes de type piperazine, agents therapeutiques
MXPA03009644A (es) Grupos azabiciclicos sustituidos para el tratamiento de enfermedades.
IL114061A0 (en) Methods of administering crf antagonists
IL145025A0 (en) Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
WO1998050383A8 (fr) Derives de 5-phenyl-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4
AU4128897A (en) Controlled release dosage form of (R-(Z))-alpha- (methoxyimino)-alpha-(1-azabicyclo(2.2.2)oct-3-yl) acetonitrile monohydrochloride
ZA913084B (en) Heterocyclic compounds their preparation and use
PT84136A (en) Process for preparing pyrrolo ]1,2-a" ]4,1" benzoxazepine deri-vatives
ZA983257B (en) 5-Aryl--3-[8-azabicyclo(3.2.1)oct-3-yl]-1,3,4-oxadiazol-2(3H)-one dericatives their preparation and their therapeutic application
IL112489A0 (en) Cyclic neurokinin a antagonists
EP1325909A4 (fr) Composes indol tricycliques possedant une affinite pour le recepteur de serotonine
TW260668B (en) Oxadiazole derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: FIGURE ADDED

WWE Wipo information: entry into national phase

Ref document number: 09403777

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1998924364

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998924364

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase in:

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1998924364

Country of ref document: EP